Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06102707

The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

Ovarian Cancer Recurrent Clinical Trial

Official title:
The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

Clinical Trial Summary

Ovarian cancer is the most lethal gynecological malignancy, posing a serious threat to women's health worldwide.Platinum resistant ovarian cancer is the biggest challenge faced by gynecological oncologists.Exploring more effective treatment options and how to delay the recurrence of platinum resistant recurrent ovarian cancer remains a challenging issue in clinical treatment.The main goal of this trial is to evaluate the effectiveness and safety of fluzopril combined with apatinib in maintenance treatment of platinum resistant recurrent ovarian cancer patients by evaluating progression free survival (PFS).Fifty patients with advanced ovarian cancer who underwent platinum resistant recurrent chemotherapy and assessed no disease progression were enrolled in the study, and maintenance treatment was performed with fluzopril combined with apatinib.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06102707
Study type Interventional
Source Qilu Hospital of Shandong University
Contact Bu Huelei
Phone 0086-0531-82169035
Email buhualei@email.sdu.edu.cn
Status Not yet recruiting
Phase N/A
Start date November 1, 2023
Completion date November 1, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06014528 - IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer Phase 2
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) Phase 1/Phase 2
Recruiting NCT03717610 - Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer N/A
Active, not recruiting NCT04175470 - Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer Phase 2
Recruiting NCT03983226 - Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) Phase 2
Recruiting NCT05095558 - Microtransplantation for Ovarian Cancer Phase 1/Phase 2
Completed NCT03657966 - DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer Phase 2
Terminated NCT03162562 - The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer Phase 1
Withdrawn NCT04149145 - Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer Phase 1
Completed NCT01332656 - Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel Phase 2
Completed NCT01111903 - A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse Phase 1/Phase 2
Recruiting NCT03734692 - Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer Phase 1/Phase 2
Recruiting NCT03827837 - Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors Phase 2
Not yet recruiting NCT05990192 - SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy Phase 2
Completed NCT01485848 - EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer Phase 2
Completed NCT03681548 - A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer. Phase 1
Recruiting NCT04072263 - Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer Phase 1/Phase 2